$43.67
1.35% yesterday
Nasdaq, Jun 27, 10:16 pm CET
ISIN
US30161Q1040
Symbol
EXEL

Exelixis, Inc. Stock price

$43.67
+0.58 1.35% 1M
+9.86 29.16% 6M
+10.37 31.14% YTD
+21.14 93.83% 1Y
+21.45 96.53% 3Y
+20.94 92.12% 5Y
+40.13 1,133.62% 10Y
+36.37 498.22% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
+0.58 1.35%
ISIN
US30161Q1040
Symbol
EXEL
Sector
Industry

Key metrics

Basic
Market capitalization
$11.9b
Enterprise Value
$10.9b
Net debt
$-1.0b
Cash
$1.0b
Shares outstanding
275.0m
Valuation (TTM | estimate)
P/E
19.58 | 16.46
P/S
5.18 | 4.52
EV/Sales
4.73 | 4.13
EV/FCF
13.25
P/B
5.64
Financial Health
Equity Ratio
76.13%
Return on Equity
23.23%
ROCE
33.41%
ROIC
39.59%
Debt/Equity
0.00
Financials (TTM | estimate)
Revenue
$2.3b | $2.6b
EBITDA
$844.3m | $1.0b
EBIT
$814.5m
Net Income
$643.6m | $729.7m
Free Cash Flow
$820.9m
Growth (TTM | estimate)
Revenue
24.50% | 21.46%
EBITDA
267.75% | 44.83%
EBIT
298.52%
Net Income
213.88% | 39.99%
Free Cash Flow
193.60%
Margin (TTM | estimate)
Gross
96.78%
EBITDA
36.73% | 39.52%
EBIT
35.43%
Net
27.99% | 27.70%
Free Cash Flow
35.71%
More
EPS
$2.23
FCF per Share
$2.98
Short interest
10.26%
Employees
1.15k
Rev per Employee
$1.89m
Show more

Is Exelixis, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Exelixis, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Exelixis, Inc. forecast:

16x Buy
62%
10x Hold
38%

Analyst Opinions

26 Analysts have issued a Exelixis, Inc. forecast:

Buy
62%
Hold
38%

Financial data from Exelixis, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Apr '25
+/-
%
2,299 2,299
24% 24%
100%
- Direct Costs 74 74
7% 7%
3%
2,225 2,225
26% 26%
97%
- Selling and Administrative Expenses 515 515
2% 2%
22%
- Research and Development Expense 895 895
14% 14%
39%
844 844
268% 268%
37%
- Depreciation and Amortization 30 30
18% 18%
1%
EBIT (Operating Income) EBIT 815 815
299% 299%
35%
Net Profit 644 644
214% 214%
28%

In millions USD.

Don't miss a Thing! We will send you all news about Exelixis, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exelixis, Inc. Stock News

Positive
Seeking Alpha
5 days ago
Exelixis is a strong buy due to robust CABOMETYX sales growth, with Q1 2025 revenues up 36% year-over-year and raised full-year 2025 guidance. Positive phase 3 STELLAR-303 results for zanzalintinib plus TECENTRIQ in non-MSI-high metastatic colorectal cancer opens significant new market opportunities. Expansion of the zanzalintinib pipeline into additional indications (nccRCC, HNSCC) and ongoing...
Positive
Investors Business Daily
5 days ago
Exelixis stock surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study.
Neutral
Business Wire
6 days ago
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-mic...
More Exelixis, Inc. News

Company Profile

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.

Head office United States
CEO Michael Morrissey
Employees 1,147
Founded 1994
Website www.exelixis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today